Global Blood Therapeutics, Inc. (GBT)
Price:
68.49 USD
( + 0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
NEWS
BMTC Group (TSE:GBT) Stock Price Crosses Below 50-Day Moving Average – What’s Next?
defenseworld.net
2026-02-07 04:38:47BMTC Group Inc. (TSE: GBT - Get Free Report) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$12.98 and traded as low as C$12.80. BMTC Group shares last traded at C$12.80, with a volume of 300 shares changing hands. BMTC Group Price Performance
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
seekingalpha.com
2022-09-16 12:41:57After a slow first half, merger and acquisition deals are heating up for the remainder of 2022. In the efforts to boost its presence in rare hematology, Pfizer recently announced it is acquiring Global Blood Therapeutics for $5.4B.
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
businesswire.com
2022-08-31 12:00:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Global Blood Therapeutics, Inc. (GBT) (NasdaqGS: GBT) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of GBT will receive $68.50 in cash for each share of GBT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR
prnewswire.com
2022-08-22 09:42:00NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atlas Air Worldwide Holdings, Inc. (NASDAQ: AAWW)'s sale to funds managed by affiliates of Apollo Global Management, Inc. and affiliates of J.F. Lehman & Company and Hill City Capital for $102.50 per share in cash.
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE, SBCF
prnewswire.com
2022-08-15 09:00:00NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Global Blood Therapeutics, Inc. (NASDAQ: GBT)'s sale to Pfizer Inc. for $68.50 per share in cash. If you are a Global Blood shareholder, click here to learn more about your rights and options.
Get ready for more merger mania in pharma sector the rest of the year
marketwatch.com
2022-08-09 14:43:00Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
zacks.com
2022-08-09 12:47:23Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Pfizer is acquiring Global Blood Therapeutics
invezz.com
2022-08-09 11:49:00Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, Global Blood Therapeutics, for $5.4 billion, representing $68.50 per GBT share.
Pfizer to buy Global Blood Therapeutics for US$5.4bn
proactiveinvestors.co.uk
2022-08-09 06:18:49Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue from its Covid-19 vaccine and treatment. Pfizer will pay US$68.50 per GBT share, which represents a 7.3% premium over Friday's closing price and nearly 43% over Thursday's closing price.
SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.
prnewswire.com
2022-08-08 15:18:00NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT), in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE). Under the terms of the merger agreement, the Company's shareholders will receive $68.50 in cash for each share of Global Blood common stock owned.
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
fool.com
2022-08-08 14:51:34The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
investorplace.com
2022-08-08 12:12:51Source: ra2 studio/Shutterstock Last week, Global Blood Therapeutics (NASDAQ: GBT ) stock was thrust into the spotlight on reports of a potential buyout bid from Pfizer (NYSE: PFE ). Today, though, Pfizer has officially disclosed that it will buy the company for $5.4 billion.
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
investors.com
2022-08-08 09:05:32Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week. The post Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics appeared first on Investor's Business Daily.
Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.
barrons.com
2022-08-08 09:01:00Pfizer said it would pay $68.50 per share for Global Blood Therapeutics which sells a sickle cell disease treatment called Oxbryta
Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion
pulse2.com
2022-08-08 07:34:20Pfizer Inc. (PFE) announced it is buying Global Blood Therapeutics (GBT) for $5.4 billion. This is why.
No data to display
BMTC Group (TSE:GBT) Stock Price Crosses Below 50-Day Moving Average – What’s Next?
defenseworld.net
2026-02-07 04:38:47BMTC Group Inc. (TSE: GBT - Get Free Report) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$12.98 and traded as low as C$12.80. BMTC Group shares last traded at C$12.80, with a volume of 300 shares changing hands. BMTC Group Price Performance
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
seekingalpha.com
2022-09-16 12:41:57After a slow first half, merger and acquisition deals are heating up for the remainder of 2022. In the efforts to boost its presence in rare hematology, Pfizer recently announced it is acquiring Global Blood Therapeutics for $5.4B.
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
businesswire.com
2022-08-31 12:00:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Global Blood Therapeutics, Inc. (GBT) (NasdaqGS: GBT) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of GBT will receive $68.50 in cash for each share of GBT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR
prnewswire.com
2022-08-22 09:42:00NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atlas Air Worldwide Holdings, Inc. (NASDAQ: AAWW)'s sale to funds managed by affiliates of Apollo Global Management, Inc. and affiliates of J.F. Lehman & Company and Hill City Capital for $102.50 per share in cash.
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE, SBCF
prnewswire.com
2022-08-15 09:00:00NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Global Blood Therapeutics, Inc. (NASDAQ: GBT)'s sale to Pfizer Inc. for $68.50 per share in cash. If you are a Global Blood shareholder, click here to learn more about your rights and options.
Get ready for more merger mania in pharma sector the rest of the year
marketwatch.com
2022-08-09 14:43:00Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
zacks.com
2022-08-09 12:47:23Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Pfizer is acquiring Global Blood Therapeutics
invezz.com
2022-08-09 11:49:00Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, Global Blood Therapeutics, for $5.4 billion, representing $68.50 per GBT share.
Pfizer to buy Global Blood Therapeutics for US$5.4bn
proactiveinvestors.co.uk
2022-08-09 06:18:49Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue from its Covid-19 vaccine and treatment. Pfizer will pay US$68.50 per GBT share, which represents a 7.3% premium over Friday's closing price and nearly 43% over Thursday's closing price.
SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.
prnewswire.com
2022-08-08 15:18:00NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT), in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE). Under the terms of the merger agreement, the Company's shareholders will receive $68.50 in cash for each share of Global Blood common stock owned.
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
fool.com
2022-08-08 14:51:34The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
investorplace.com
2022-08-08 12:12:51Source: ra2 studio/Shutterstock Last week, Global Blood Therapeutics (NASDAQ: GBT ) stock was thrust into the spotlight on reports of a potential buyout bid from Pfizer (NYSE: PFE ). Today, though, Pfizer has officially disclosed that it will buy the company for $5.4 billion.
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
investors.com
2022-08-08 09:05:32Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week. The post Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics appeared first on Investor's Business Daily.
Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.
barrons.com
2022-08-08 09:01:00Pfizer said it would pay $68.50 per share for Global Blood Therapeutics which sells a sickle cell disease treatment called Oxbryta
Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion
pulse2.com
2022-08-08 07:34:20Pfizer Inc. (PFE) announced it is buying Global Blood Therapeutics (GBT) for $5.4 billion. This is why.